JP2002501484A5 - - Google Patents

Download PDF

Info

Publication number
JP2002501484A5
JP2002501484A5 JP1998538801A JP53880198A JP2002501484A5 JP 2002501484 A5 JP2002501484 A5 JP 2002501484A5 JP 1998538801 A JP1998538801 A JP 1998538801A JP 53880198 A JP53880198 A JP 53880198A JP 2002501484 A5 JP2002501484 A5 JP 2002501484A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998538801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002501484A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/004303 external-priority patent/WO1998039363A2/en
Publication of JP2002501484A publication Critical patent/JP2002501484A/ja
Publication of JP2002501484A5 publication Critical patent/JP2002501484A5/ja
Ceased legal-status Critical Current

Links

JP53880198A 1997-03-05 1998-03-05 免疫毒素および免疫寛容を誘導する方法 Ceased JP2002501484A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3998797P 1997-03-05 1997-03-05
US60/039,987 1997-03-05
PCT/US1998/004303 WO1998039363A2 (en) 1997-03-05 1998-03-05 Immunotoxins and methods of inducing immune tolerance

Publications (2)

Publication Number Publication Date
JP2002501484A JP2002501484A (ja) 2002-01-15
JP2002501484A5 true JP2002501484A5 (enExample) 2005-11-10

Family

ID=21908461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53880198A Ceased JP2002501484A (ja) 1997-03-05 1998-03-05 免疫毒素および免疫寛容を誘導する方法

Country Status (8)

Country Link
US (2) US6632928B1 (enExample)
EP (1) EP1015496B1 (enExample)
JP (1) JP2002501484A (enExample)
AT (1) ATE433998T1 (enExample)
AU (1) AU733898B2 (enExample)
CA (1) CA2284079C (enExample)
DE (1) DE69840913D1 (enExample)
WO (1) WO1998039363A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
WO2001087982A2 (en) * 2000-05-18 2001-11-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US6632928B1 (en) 1997-03-05 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7125553B1 (en) 1996-04-15 2006-10-24 The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention Methods of inducing immune tolerance using immunotoxins
CA2358435A1 (en) * 1999-01-08 2000-07-13 Stuart J. Knechtle Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
JP2002541195A (ja) * 1999-04-14 2002-12-03 アメリカ合衆国 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物
WO2000078348A1 (en) * 1999-06-17 2000-12-28 University Of Vermont And State Agricultural College Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells
US6492498B1 (en) 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
AU2002325164B2 (en) * 2001-07-24 2008-12-04 Debiovision Inc. Receptor, the use thereof, and mouse antibodies
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US7105347B2 (en) 2002-07-30 2006-09-12 Corning Incorporated Method and device for protein delivery into cells
US7691580B2 (en) * 2003-01-29 2010-04-06 Corning Incorporated Reverse protein delivery into cells on coded microparticles
US20090029460A1 (en) * 2004-01-26 2009-01-29 Peter Vollmers Neoplasm-specific polypeptides and their uses
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
AU2006306521B2 (en) * 2005-10-21 2011-12-22 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by TLR ligands and uses thereof
WO2008088422A2 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
PT2197903E (pt) * 2007-09-04 2015-01-02 Us Gov Health & Human Serv Delecções no domínio ii da exotoxina a de pseudomonas que reduzem toxicidade não específica
PE20120630A1 (es) * 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
EP2565667A1 (en) 2011-08-31 2013-03-06 Friedrich-Alexander-Universität Erlangen-Nürnberg Direction of arrival estimation using watermarked audio signals and microphone arrays
WO2025050404A1 (zh) * 2023-09-08 2025-03-13 成都维瑾柏鳌生物医药科技有限公司 一种药物组合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520226A (en) 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
ATE101162T1 (de) 1985-11-13 1994-02-15 Hospital Univ Durch cys-kodon modifizierte dns.
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
WO1989006968A1 (en) 1988-02-03 1989-08-10 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
IL89504A0 (en) 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
CA2076753A1 (en) 1990-02-26 1991-08-27 Anthony J. Radford Shuttle plasmid for escherichia coli and mycobacteria
US5167956A (en) 1991-02-11 1992-12-01 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in-vivo t cell suppressant activity
US5725857A (en) 1991-02-11 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
WO1993015113A1 (en) 1992-01-24 1993-08-05 Tanox Biosystems, Inc. An immunotoxin including a cytotoxin with an unpaired cysteine residue in or near its receptor-binding site
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US5688781A (en) 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
DE69638145D1 (de) * 1995-04-14 2010-04-22 Us Gov Health & Human Serv Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
US6103235A (en) 1995-10-30 2000-08-15 The United States Of America As Represented By The Department Of Health And Human Services Methods of inducing immune tolerance using immunotoxins
US6632928B1 (en) 1997-03-05 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
US5747474A (en) * 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
EP0968282A2 (en) 1997-03-05 2000-01-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vectors and methods for expression of mutant proteins
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
AU3654499A (en) 1998-04-22 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
CA2358435A1 (en) 1999-01-08 2000-07-13 Stuart J. Knechtle Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
JP2002541195A (ja) 1999-04-14 2002-12-03 アメリカ合衆国 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物

Similar Documents

Publication Publication Date Title
JP2000509912A5 (enExample)
JP2000509637A5 (enExample)
JP2000507042A5 (enExample)
JP2000509635A5 (enExample)
JP2000509942A5 (enExample)
JP2000510751A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2000508680A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510969A5 (enExample)
JP2002501484A5 (enExample)
JP2000508836A5 (enExample)
JP2000508102A5 (enExample)
JP2000509520A5 (enExample)
JP2000509818A5 (enExample)
JP2000507434A5 (enExample)
JP2000508880A5 (enExample)